News from pharmamar A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

28 Apr, 2020, 11:39 BST PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with...


31 Jul, 2018, 10:25 BST PharmaMar Announces That the ATLANTIS Study Has Reached the Goal of Patient Recruitment

ATLANTIS study, in small-cell lung cancer with lurbinectedin, recruited 600 patients in a total of 160 hospital centers in 20 countries Top line data ...


27 Jul, 2018, 13:18 BST PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis® in the Nordic Countries and Eastern Europe

PharmaMar will receive an up-front payment of 2 million euros This agreement will replace the current agreement between PharmaMar and Swedish Orphan...


11 Jun, 2018, 13:30 BST PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® With Pint Pharma International

PharmaMar (MCE: PHM) has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A....


05 Jun, 2018, 13:30 BST PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin

Abstract #8018 The modelled data on overall survival of the statistical evaluation of the impact of crossover on the ADMYRE study were presented. Of...


04 Jun, 2018, 13:30 BST PharmaMar Presents New Results with Lurbinectedin as a Single Agent in Patients with Recurrent Small-cell Lung Cancer at ASCO 2018

Abstract #8570 The phase II basket trial, which began recruiting 15 patients with recurrent small-cell lung cancer, was increased to target enrolment ...


14 Feb, 2018, 13:30 GMT PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates

PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which...


03 Jan, 2018, 12:36 GMT PharmaMar has Requested the Process of Re-Examination for Aplidin® from the EMA

PharmaMar (MCE: PHM) has announced the initiation of the re-examination process by the European Medicines Agency (EMA) for Aplidin® (plitidepsin) for ...


02 Jan, 2018, 16:48 GMT PharmaMar Signs a Commercialization and Distribution License Agreement for Aplidin® (plitidepsin) with Megapharm in Israel

PharmaMar (MCE:PHM) has announced today a commercialization and distribution license agreement with Megapharm Ltd. for the marine-derived anticancer...


14 Nov, 2017, 08:30 GMT GENOMICA Receives Authorization for the Commercialization of its Diagnostic Kits and Instruments in South Korea

GENOMICA, a leading molecular diagnostics company belonging to the PharmaMar Group (MCE: PHM), has announced that it has received authorization in...


20 Sep, 2017, 08:30 BST PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors

With the motivation of finding a solution to the unmet needs of patients with different types of cancer, PharmaMar (MCE: PHM) announces the start of...


12 Sep, 2017, 08:30 BST New Positive Data on PM1183 Sees a Response Rate of 36% as Single Agent in Patients With Advanced and Relapsed Small-Cell Lung Cancer

PharmaMar (MSE: PHM) presented during the European Society for Medical Oncology congress (ESMO), held in Madrid, positive results of PM1183...


31 Aug, 2017, 14:52 BST PharmaMar Will Present New Clinical Data on PM1183 During ESMO 2017

PharmaMar (MCE: PHM) will present the clinical data obtained from various clinical studies carried out with its antitumoral compounds of marine...


13 Jun, 2017, 10:00 BST PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers

PharmaMar (MCE: PHM) has participated in the Annual Meeting of the American society of Clinical Oncology (ASCO) with new data with inhibitors of...


01 Jun, 2017, 09:00 BST Sylentis Initiates a Phase III Study for the Treatment of Dry Eye Syndrome

The pharmaceutical Company Sylentis (PharmaMar Group) has announced the start of the first Phase III study, HELIX, with the investigational new drug, ...


25 May, 2017, 15:31 BST PharmaMar and Eczacıbaşı Sign a Licensing Agreement for Aplidin® in Turkey

PharmaMar (MCE:PHM) has announced today a licensing agreement with Eczacıbaşı Group to commercialize the marine-derived anticancer drug Aplidin®...


19 May, 2017, 09:00 BST PharmaMar Announces New Data with its Compounds Yondelis® and Lurbinectedin During ASCO 2017

PharmaMar (MCE: PHM) will present data obtained from various clinical studies for its activated transcription inhibitors, Yondelis® and...


28 Nov, 2016, 00:05 GMT PharmaMar Begins a Phase I Study of PM1183 in Japan for the Treatment of Solid Tumors

PharmaMar (MSE:PHM) has announced the start of an open-label, multicenter, Phase I study in Japan to evaluate the recommended dose (RD) of PM1183...


10 Nov, 2016, 08:45 GMT PharmaMar Shows New Clinical Data With Yondelis® in Different Sarcoma Subtypes at CTOS 2016

Within the framework of the 21st Annual Meeting of the Connective Tissue Oncology Society (CTOS), that is taking place from the 9th of November until ...


31 Oct, 2016, 09:00 GMT PharmaMar is Present at the 16th International Gynecologic Cancer Society Meeting With New Evidence on Yondelis®

PharmaMar (MCE:PHM) presents the new data obtained from several clinical studies carried out with its antitumor compound of marine origin, Yondelis®, ...


28 Oct, 2016, 08:45 BST The EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin®

PharmaMar (MSE: PHM) has announced today that the European Medicines Agency (EMA) has accepted to assess the Marketing Authorization Application...


10 Oct, 2016, 09:00 BST PharmaMar Announces Positive Results From its Phase II Study With lurbinectedin in BRCA 1/2 - Associated Metastatic Breast Cancer at the ESMO 2016 Congress

The data was presented at an oral session at the European Society of Medical Oncology (abstract #2333) The study meets its primary objective...


22 Sep, 2016, 09:00 BST PharmaMar Submits MAA to EMA for Aplidin® for the Treatment of Multiple Myeloma

PharmaMar (MSE:PHM) has announced today the submission to the European Medicines Agency (EMA) of the Marketing Authorization Application (MAA) for...


11 Aug, 2016, 09:00 BST PharmaMar Announces the IDMC´s Response on the CORAIL Trial Using PM1183

PharmaMar (MCE: PHM) announces that it has received the approval from the Independent Data Monitoring Committee (IDMC) to continue with the pivotal...


02 Aug, 2016, 09:00 BST PharmaMar Initiates a Pivotal Phase III ATLANTIS Study with PM1183 in Combination with Doxorubicin in Patients with Small Cell Lung Cancer

PharmaMar (MSE:PHM) today announced the start of a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 (lurbinectedin) in...